{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T02:26:12Z","timestamp":1769826372657,"version":"3.49.0"},"reference-count":26,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T00:00:00Z","timestamp":1769731200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Pfizer Canada ULC"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Oncology"],"abstract":"<jats:p>Canadian real-world data (RWD) regarding palbociclib as a first-line therapy for patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2\u2212) metastatic breast cancer (MBC) is limited. The PALbociclib CANadian (PALCAN) study examined palbociclib utilization patterns as first-line treatment for HR+\/HER2\u2212 MBC using Alberta health administrative data. The final PALCAN cohort included 472 female patients with a median age of 64 years and a median follow-up time of 22.8 months (IQR: 0.7\u201388.2). The median (95% CI) duration of treatment was 13.8 (12.7\u201315.1) months in the overall cohort (IQR: 5.6, 24.8 months), and the probability of treatment discontinuation within the first year was 45%. Aromatase inhibitors (AIs) and fulvestrant were the accompanying endocrine therapies (ETs) in 83% (N = 393) and 14% (N = 64) (15 with unknown accompanying therapy) of patients, respectively. The median duration of treatment for patients receiving an AI as an accompanying therapy was 15.1 (13.6\u201317.4) months and 7.9 months (5.8\u201312.6) for patients receiving fulvestrant, which may suggest endocrine resistance in the latter group. The PALCAN data provides insights into practice patterns and the effectiveness of palbociclib as a first-line therapy in female patients with HR+\/HER2\u2212 breast cancer in the Canadian real-world setting.<\/jats:p>","DOI":"10.3390\/curroncol33020081","type":"journal-article","created":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T13:04:46Z","timestamp":1769778286000},"page":"81","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Real-World Utilization of Palbociclib as First-Line Treatment for Canadian HR+\/HER2\u2212 Women with Metastatic Breast Cancer: Results from PALCAN Study"],"prefix":"10.3390","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2438-3128","authenticated-orcid":false,"given":"Daniel","family":"Rayson","sequence":"first","affiliation":[{"name":"Division of Medical Oncology, Dalhousie University, Halifax, NS B3H 2Y9, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan","family":"Bertin","sequence":"additional","affiliation":[{"name":"Pfizer Canada ULC, Kirkland, QC H9J 2M5, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maxim","family":"Lemelin","sequence":"additional","affiliation":[{"name":"Pfizer Canada ULC, Kirkland, QC H9J 2M5, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Madeline","family":"Tong","sequence":"additional","affiliation":[{"name":"IQVIA Solutions Canada, Kirkland, QC H9J 2M5, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9929-3645","authenticated-orcid":false,"given":"Ryan","family":"Ng","sequence":"additional","affiliation":[{"name":"IQVIA Solutions Canada, Kirkland, QC H9J 2M5, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philip","family":"Ding","sequence":"additional","affiliation":[{"name":"Oncology Outcomes Research Program, University of Calgary, Calgary, AB T2N 4N1, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Winson Y.","family":"Cheung","sequence":"additional","affiliation":[{"name":"Oncology Outcomes Research Program, University of Calgary, Calgary, AB T2N 4N1, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arushi","family":"Sharma","sequence":"additional","affiliation":[{"name":"IQVIA Solutions Canada, Kirkland, QC H9J 2M5, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Phu Vinh","family":"On","sequence":"additional","affiliation":[{"name":"Pfizer Canada ULC, Kirkland, QC H9J 2M5, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guillaume","family":"Feug\u00e8re","sequence":"additional","affiliation":[{"name":"Pfizer Canada ULC, Kirkland, QC H9J 2M5, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9545-0802","authenticated-orcid":false,"given":"Sasha","family":"Lupichuk","sequence":"additional","affiliation":[{"name":"Oncology Outcomes Research Program, University of Calgary, Calgary, AB T2N 4N1, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2026,1,30]]},"reference":[{"key":"ref_1","unstructured":"Canadian Cancer Statistics Advisory Committee in Collaboration with the Canadian Cancer Society, Statistics Canada and the Public Health Agency of Canada (2025, December 07). Canadian Cancer Statistics 2025. Available online: https:\/\/cancer.ca\/Canadian-Cancer-Statistics-2025-EN."},{"key":"ref_2","unstructured":"Canadian Cancer Survivor Network (2025, April 24). Statistics and Research in Metastatic Breast Cancer. Available online: https:\/\/survivornet.ca\/cancer-type\/breast-cancer\/metastatic-breast-cancer\/statistics-and-research-in-metastatic-breast-cancer\/."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"e191","DOI":"10.3747\/co.27.5769","article-title":"A population-based analysis of breast cancer incidence and survival by subtype in Ontario women","volume":"27","author":"Seung","year":"2020","journal-title":"Curr. Oncol."},{"key":"ref_4","unstructured":"Canadian Cancer Society (2025, April 24). Survival Statistics for Breast Cancer. Available online: https:\/\/cancer.ca\/en\/cancer-information\/cancer-types\/breast\/prognosis-and-survival\/survival-statistics."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Zubair, M., Wang, S., and Ali, N. (2020). Advanced Approaches to Breast Cancer Classification and Diagnosis. Front. Pharmacol., 11.","DOI":"10.3389\/fphar.2020.632079"},{"key":"ref_6","unstructured":"National Cancer Institute (2025, April 24). Bethesda MD SEER Cancer Stat Facts: Female Breast Cancer, Available online: https:\/\/seer.cancer.gov\/statfacts\/html\/breast.html."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1158\/1055-9965.EPI-16-0520","article-title":"Cancer Incidence and Survival Trends by Subtype Using Data from the Surveillance Epidemiology and End Results Program, 1992\u20132013","volume":"26","author":"Noone","year":"2017","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"key":"ref_8","unstructured":"(2025, April 24). Metastatic Breast Cancer. Available online: http:\/\/www.bccancer.bc.ca\/books\/breast\/management\/metastatic-breast-cancer."},{"key":"ref_9","unstructured":"(2025, April 24). NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae). Breast Cancer. Available online: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/breast.pdf."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1016\/j.annonc.2021.09.019","article-title":"ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer","volume":"32","author":"Gennari","year":"2021","journal-title":"Ann. Oncol."},{"key":"ref_11","unstructured":"(2025, April 25). Ibrance (Palbociclib). Product Monograph. Pfizer Canada ULC. Available online: https:\/\/www.pfizer.ca\/en\/our-products\/ibrance-palbociclib."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"e749","DOI":"10.1002\/onco.13684","article-title":"Long-Term Pooled Safety Analysis of Palbociclib in Combination with Endocrine Therapy for Hormone Receptor-Positive\/Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Updated Analysis with up to 5 Years of Follow-Up","volume":"26","author":"Finn","year":"2021","journal-title":"Oncologist"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2270","DOI":"10.3390\/curroncol28030209","article-title":"First-Line Treatment with a Cyclin-Dependent Kinase 4\/6 Inhibitor Plus an Aromatase Inhibitor for Metastatic Breast Cancer in Alberta","volume":"28","author":"Amaro","year":"2021","journal-title":"Curr. Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2172","DOI":"10.3390\/curroncol31040161","article-title":"Real-World Treatment Patterns and Clinical Outcomes among Patients Receiving CDK4\/6 Inhibitors for Metastatic Breast Cancer in a Canadian Setting Using AI-Extracted Data","volume":"31","author":"Moulson","year":"2024","journal-title":"Curr. Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/j.clbc.2022.05.002","article-title":"Real-World Treatment Patterns and Outcomes of Palbociclib Plus an Aromatase Inhibitor for Metastatic Breast Cancer: Flatiron Database Analysis","volume":"22","author":"Patt","year":"2022","journal-title":"Clin. Breast Cancer"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.2217\/fon-2023-0176","article-title":"Real-world outcomes of patients with metastatic endocrine-responsive breast cancer receiving palbociclib-based combinations","volume":"19","author":"Moser","year":"2023","journal-title":"Future Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"678","DOI":"10.3390\/curroncol28010066","article-title":"Real-World Palbociclib Use in HR+\/HER2- Advanced Breast Cancer in Canada: The IRIS Study","volume":"28","author":"Mycock","year":"2021","journal-title":"Curr. Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"349","DOI":"10.2217\/fon-2021-0716","article-title":"Real-world treatment of patients with palbociclib for HR+\/HER2-advanced\/metastatic breast cancer: The Europe IRIS study","volume":"18","author":"Mycock","year":"2022","journal-title":"Future Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"JGO1800239","DOI":"10.1200\/JGO.18.00239","article-title":"Real-World Treatment Patterns and Clinical Outcomes in Patients Receiving Palbociclib for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced or Metastatic Breast Cancer in Argentina: The IRIS Study","volume":"5","author":"Waller","year":"2019","journal-title":"J. Glob. Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"e2549109","DOI":"10.1001\/jamanetworkopen.2025.49109","article-title":"Adjuvant Chemotherapy Use for Hormone Receptor\u2013Positive, ERBB2-Negative Breast Cancer After RxPONDER Trial","volume":"8","author":"Freeman","year":"2025","journal-title":"JAMA Netw. Open"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.breast.2021.07.017","article-title":"Efficacy and safety of palbociclib in patients with estrogen receptor-positive\/human epidermal growth factor receptor 2-negative advanced breast cancer with preexisting conditions: A post hoc analysis of PALOMA-2","volume":"59","author":"Gelmon","year":"2021","journal-title":"Breast"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.breast.2023.01.001","article-title":"A systematic review of the impact of the COVID-19 pandemic on breast cancer screening and diagnosis\u2014The Breast","volume":"67","author":"Li","year":"2024","journal-title":"Breast"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.breast.2022.02.005","article-title":"Real-world effectiveness of palbociclib plus fulvestrant in advanced breast cancer: Results from a population-based cohort study","volume":"62","author":"Ramos","year":"2022","journal-title":"Breast"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1056\/NEJMoa1810527","article-title":"Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer","volume":"20","author":"Turner","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1055\/a-1519-7089","article-title":"AGO Algorithms for the Treatment of Breast Cancer: Update 2021","volume":"81","author":"Schneeweiss","year":"2021","journal-title":"Geburtshilfe Frauenheilkd"},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Kim, J.-Y., Shin, J., Ahn, J.S., Park, Y.H., and Im, Y.-H. (2023). Real World Experience of Second-Line Treatment Strategies after Palbociclib and Letrozole: Overall Survival in Metastatic Hormone Receptor-Positive Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer. Cancers, 15.","DOI":"10.3390\/cancers15133431"}],"container-title":["Current Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1718-7729\/33\/2\/81\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T13:21:53Z","timestamp":1769779313000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1718-7729\/33\/2\/81"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,30]]},"references-count":26,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,2]]}},"alternative-id":["curroncol33020081"],"URL":"https:\/\/doi.org\/10.3390\/curroncol33020081","relation":{},"ISSN":["1718-7729"],"issn-type":[{"value":"1718-7729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,30]]}}}